Soleus Capital
Soleus Capital is a private equity firm.
Business Model:
Revenue: $0
Employees: 0-0
Rankings
Industries / Tags:
Detailed Soleus Capital Information
Geographic Data
Address: 104 Field Point Road
City: Greenwich
State: CT
Zip: 06830
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$137M
Social
Linkedin
Crunchbase
Metrics
0Website Global Rank
0Website Monthly Traffic
Twitter Followers
Description
Soleus Capital is a private equity firm.
Contact Phone:
+14752083178
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 4/2021 | Antios Therapeutics | Series B | 0 |
| 11/2020 | SomaLogic | Series A | 0 |
| 12/2021 | Freenome | Series D | 300M |
| 8/2020 | Freenome | Series C | 270M |
| 7/2020 | Verona Pharma | Private Placement | 200M |
| 5/2021 | TwinStrand Biosciences | Series B | 50M |
| 9/2022 | RayzeBio | Series D | 160M |
| 1/2021 | IO Biotech | Series B | 0 |
| 8/2020 | NeuroPace | Venture Round | 33M |
| 1/2020 | Lyra Therapeutics | Series C | 0 |
| 9/2020 | Galecto | Series D | 0 |
| 7/2019 | Freenome | Series B | 160M |
| 7/2019 | Beta Bionics | Series B | 63M |
| 3/2019 | Orchestra BioMed | Series B | 34M |
| 11/2021 | Antios Therapeutics | Series B | 0 |
| 9/2021 | Obsidian Therapeutics | Series B | 0 |
| 1/2021 | Dice Therapeutics | Series C | 80M |
| 6/2021 | Notal Vision | Series D | 0 |
| 3/2021 | Field Trip Health | Post-IPO Equity | 0 |
| 8/2020 | Mission Bio | Series C | 0 |
| 7/2020 | BioAtla | Series D | 0 |
| 11/2022 | BioAtla | Post-IPO Equity | 0 |
| 9/2021 | INBRACE | Series D | 0 |
| 1/2021 | Werewolf Therapeutics | Series B | 0 |
| 4/2020 | COMPASS Pathways | Series B | 0 |
| 5/2022 | Celcuity | Post-IPO Equity | 0 |
| 7/2020 | DarioHealth | Post-IPO Equity | 28.6M |
| 4/2022 | LimFlow SA | Series D | 0 |
| 2/2021 | Q&s;Apel Medical | Series C | 22M |
| 2/2022 | Beta Bionics | Series C | 0 |
| 9/2018 | Lyra Therapeutics | Series B | 0 |
| 2/2021 | Inivata | Series C | 35M |
| 2/2022 | Parse Biosciences | Series B | 0 |
| 5/2021 | NeoGenomics | Post-IPO Equity | 0 |
| 5/2021 | Genapsys | Series D | 0 |
| 12/2019 | ArcherDX | Series C | 0 |
| 9/2021 | BioAtla | Post-IPO Equity | 0 |
| 8/2021 | Dice Therapeutics | Series C | 60M |
| 7/2021 | Artios Pharma | Series C | 0 |
| 5/2022 | Celcuity | Post-IPO Equity | 0 |
| 4/2022 | LimFlow SA | Series D | 0 |
| 2/2022 | Beta Bionics | Series C | 0 |
| 2/2022 | Parse Biosciences | Series B | 0 |
| 12/2021 | Freenome | Series D | 0 |
| 11/2021 | Antios Therapeutics | Series B | 0 |
| 9/2021 | BioAtla | Post-IPO Equity | 0 |
| 9/2021 | Obsidian Therapeutics | Series B | 0 |
| 9/2021 | INBRACE | Series D | 0 |
| 8/2021 | Dice Therapeutics | Series C | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
